

Claim Listing

This listing of claims will replace all prior versions, and listings, of claims in the application.

1-14. Cancelled.

15. (Currently amended) A fused or chimeric polypeptide ~~comprising~~
consisting essentially of:

a first component including a polypeptide ~~that specifically binds to at least one of $\alpha 6\beta 1$ integrin receptor and $\alpha 6\beta 4$ integrin receptor, wherein the polypeptide comprises~~ consisting of the G3 subdomain of the laminin-5 $\alpha 3$ chain ~~or a fragment, homolog, or ortholog thereof, and~~

a second component chemically bound to said first component, wherein said second component consists of interleukin-2 ~~includes an agent for use in the destruction or neutralization of a pathogen comprising at least one of $\alpha 6\beta 1$ integrin receptor and $\alpha 6\beta 4$ integrin receptor on the surface of the pathogen.~~

16-45. Cancelled.

46. (Previously presented) The fused or chimeric polypeptide of claim 15, wherein the first component consists of SEQ ID NO:6.

47-56. Cancelled.

57. (New) A fused or chimeric polypeptide consisting essentially of:
a first component consisting of the G1 to G3 subdomain of the laminin-5 $\alpha 3$ chain, and

a second component chemically bound to said first component, wherein said second component consists of interleukin-2.

58. (New) The fused or chimeric polypeptide of claim 15, wherein the first component consists of SEQ ID NO:4.

59. (New) A fused or chimeric polypeptide consisting essentially of:
a first component consisting of the complete globular domain of the laminin-5 $\alpha 3$ chain, and

a second component chemically bound to said first component, wherein said second component consists of interleukin-2.

60. (New) The fused or chimeric polypeptide of claim 15, wherein the first component consists of SEQ ID NO:2.